Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATIC | P31939 | 1/20 | 0.42 |
| ▸ | ACLY | P53396 | 4/20 | 0.39 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.39 |
| ▸ | SLC22A12 | Q96S37 | 3/20 | 0.37 |
| ▸ | MOGAT2 | Q3SYC2 | 2/20 | 0.37 |
| ▸ | APP | P05067 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31086045 | 0.92 | ATIC (0.40) | ATICACLYCRBNSLC22A12MOGAT2 | |
| SCHEMBL31086172 | 0.91 | ATIC (0.44) | ATICACLYCRBNSLC22A12MOGAT2 | |
| SCHEMBL24697648 | 0.91 | ATIC (0.41) | ATICACLYCRBNMOGAT2MAPT | |
| SCHEMBL31086076 | 0.91 | ATIC (0.41) | ATICACLYCRBNMOGAT2MAPT | |
| SCHEMBL31085975 | 0.90 | ATIC (0.43) | ATICACLYCRBNSLC22A12LMNA | |
| SCHEMBL31085832 | 0.90 | CRBN (0.42) | ATICACLYCRBNMOGAT2MAPT | |
| SCHEMBL31085700 | 0.89 | ATIC (0.41) | ATICACLYCRBNMOGAT2APP | |
| SCHEMBL24697642 | 0.89 | ATIC (0.41) | ATICACLYCRBNMOGAT2APP | |
| SCHEMBL24696659 | 0.88 | CRBN (0.47) | ATICACLYCRBNMOGAT2MAPT | |
| SCHEMBL31085788 | 0.88 | CRBN (0.47) | ATICACLYCRBNMOGAT2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240299385-A1 | 3-PYRROLYLSULFONAMIDE COMPOUNDS AS GPR17 ANTAGONISTS | REWIND THERAPEUTICS NV (BE) | 2024-09-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240299385-A1 | 3-PYRROLYLSULFONAMIDE COMPOUNDS AS GPR17 ANTAGONISTS | GPR3, GPR27, GPR65 | ATIC 1528/4885ACLY 2461/4885CRBN 4472/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.